Matrix metalloproteases and PAR1 activation

Blood

Volumn 121, Issue 3, 2013, Pages 431-439

  Austin, Karyn M ^a   Covic, Lidija ^a,b   Kuliopulos, Athan ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; COLLAGEN FIBRIL; COLLAGENASE 3; CP 471474; DOXYCYCLINE; ENZYME PRECURSOR; FN 439; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; PD 166793; PG 116800; PROTEINASE ACTIVATED RECEPTOR 1; STROMELYSIN; THROMBIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTERY THROMBOSIS; CAROTID ATHEROSCLEROSIS; DRUG EFFECT; ENZYME INHIBITION; FIBROBLAST; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HUMAN; IC 50; IN-STENT RESTENOSIS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 84872461768     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-355958     Document Type: Review

References (110)

1. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation. 2006;114(10):1070-1077. (Pubitemid 44358884)
2. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64(6):1057-1068. (Pubitemid 121001193)
3. Rasmussen UB, Vouret-Craviari V, Jallat S, et al. cDNA cloning and expression of a hamster alphathrombin receptor coupled to Ca2+ mobilization. FEBS Lett. 1991;288(1):123-128.
4. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800-1814. (Pubitemid 41716567)
5. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry. 1999;38(14):4572-4585.
6. Santos BF, Serrano SM, Kuliopulos A, Niewiarowski S. Interaction of viper venom serine peptidases with thrombin receptors on human platelets. FEBS Lett. 2000;477(3):199-202. (Pubitemid 30450166)
7. Koukos G, Sevigny L, Zhang P, Covic L, Kuliopulos A. Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury. IUBMB Life. 2011;63(6):412-418.
8. Adams MN, Ramachandran R, Yau MK, et al. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther. 2011; 130(3):248-282.
9. Lee H, Sturgeon SA, Jackson SP, Hamilton JR. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions. Thromb Haemost. 2012;107(2):328-337.
10. Veiga Cde S, Carneiro-Lobo TC, Coelho CJ, et al. Increased expression of protease-activated receptor 1 (PAR-1) in human leukemias. Blood Cells Mol Dis. 2011;46(3):230-234.
11. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53(2):245-282. (Pubitemid 32476117)
12. Trivedi V, Boire A, Tchernychev B, et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell. 2009;137(2):332-343.
13. Galt SW, Lindemann S, Allen L, et al. Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res. 2002;90(10): 1093-1099. (Pubitemid 34627908)
14. Jaffre F, Friedman AE, Hu Z, Mackman N, Blaxall BC. Beta-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation. 2012;125(24): 2993-3003.
15. Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta. 2010;1803(1):39-54.
16. Manka SW, Carafoli F, Visse R, et al. Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1. Proc Natl Acad Sci U S A. 2012;109(31):12461-12466.
17. Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 2009;78:929-958.
18. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol. 2012;56(5):232-244.
19. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003;59(4):812-823. (Pubitemid 38366237)
20. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562-573. (Pubitemid 43139720)
21. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004;4(8):617-629. (Pubitemid 39025047)
22. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516. (Pubitemid 33096184)
23. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120(3):303-313. (Pubitemid 40222426)
24. Tressel SL, Kaneider NC, Kasuda S, et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 2011;3(7):370-384.
25. Foley CJ, Luo C, O'Callaghan K, Hinds PW, Covic L, Kuliopulos A. Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J Biol Chem. 2012;287(29):24330-24338.
26. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94(6):2493-2503. (Pubitemid 24379627)
27. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000;6(12):4823-4830. (Pubitemid 32110426)
28. Giambernardi TA, Grant GM, Taylor GP, et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol. 1998;16(8): 483-496. (Pubitemid 28132527)
29. Balbin M, Fueyo A, Knauper V, et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem. 2001;276(13):10253-10262.
30. Kiili M, Cox SW, Chen HY, et al. Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. J Clin Periodontol. 2002;29(3):224-232. (Pubitemid 41697858)
31. Moilanen M, Sorsa T, Stenman M, et al. Tumorassociated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry. 2003;42(18):5414-5420. (Pubitemid 36560438)
32. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999;99(19):2503-2509. (Pubitemid 29228279)
33. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem. 2001;276(30):28261- 28267.
34. Jin F, Zhai Q, Qiu L, et al. Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization. Bone Marrow Transplant. 2008;42(9):581-588.
35. Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009;23(16):1882-1894.
36. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem. 1996;271(25):14657-14660. (Pubitemid 26194936)
37. Seeley S, Covic L, Jacques SL, Sudmeier J, Baleja JD, Kuliopulos A. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem Biol. 2003;10(11):1033-1041. (Pubitemid 37496433)
38. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature. 1991;353(6345):674-677. (Pubitemid 21912589)
39. Swift S, Leger AJ, Talavera J, Zhang L, Bohm A, Kuliopulos A. Role of the PAR1 receptor 8th helix in signaling: the 7-8-1 receptor activation mechanism. J Biol Chem. 2006;281(7):4109-4116. (Pubitemid 43847837)
40. Jacques SL, LeMasurier M, Sheridan PJ, Seeley SK, Kuliopulos A. Substrate-assisted catalysis of the PAR1 thrombin receptor: enhancement of macromolecular association and cleavage. J Biol Chem. 2000; 275(52):40671-40678. (Pubitemid 32054883)
41. Harris JL, Backes BJ, Leonetti F, Mahrus S, Ellman JA, Craik CS. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci U S A. 2000;97(14):7754-7759. (Pubitemid 30460720)
42. Nieman MT, Schmaier AH. Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry. 2007;46(29):8603-8610. (Pubitemid 47106111)
43. Jacques SL, Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. Biochem J. 2003;376(3):733-740. (Pubitemid 38058072)
44. Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry. 2000;39(18):5458-5467. (Pubitemid 30257087)
45. Blackburn JS, Brinckerhoff CE. Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. Am J Pathol. 2008;173(6):1736-1746.
46. Yang E, Boire A, Agarwal A, et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 2009;69(15):6223- 6231.
47. Netzel-Arnett S, Fields GB, Birkedal-Hansen H, Van Wart HE. Sequence specificities of human fibroblast and neutrophil collagenases. J Biol Chem. 1991;266(11):6747-6755. (Pubitemid 21906285)
48. Turk BE, Huang LL, Piro ET, Cantley LC. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol. 2001;19(7):661-667. (Pubitemid 32625438)
49. Lovejoy B, Welch AR, Carr S, et al. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol. 1999;6(3):217-221. (Pubitemid 29107223)
50. BodeW, Reinemer P, Huber R, Kleine T, Schnierer S, Tschesche H. The x-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J. 1994;13(6): 1263-1269. (Pubitemid 24090206)
51. Berman J, Green M, Sugg E, et al. Rapid optimization of enzyme substrates using defined substrate mixtures. J Biol Chem. 1992;267(3):1434-1437.
52. Chang JY. Thrombin specificity: requirement for apolar amino acids adjacent to the thrombin cleavage site of polypeptide substrate. Eur J Biochem. 1985;151(2):217-224.
53. Nesi A, Fragai M. Substrate specificities of matrix metalloproteinase 1 in PAR-1 exodomain proteolysis. Chembiochem. 2007;8(12):1367-1369. (Pubitemid 47300327)
54. Schuepbach RA, Madon J, Ender M, Galli P, Riewald M. Protease activated receptor-1 cleaved at R46 mediates cytoprotective effects. J Thromb Haemost. 2012;10(8):1675-1684.
55. Kaneider NC, Leger AJ, Agarwal A, et al. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol. 2007;8(12): 1303-1312. (Pubitemid 350131169)
56. Sevigny LM, Austin KM, Zhang P, et al. Proteaseactivated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler Thromb Vasc Biol. 2011;31(12):e100-e106.
57. Ayoub MA, Maurel D, Binet V, et al. Real-time analysis of agonist-induced activation of protease-activated receptor 1/Galphai1 protein complex measured by bioluminescence resonance energy transfer in living cells. Mol Pharmacol. 2007;71(5):1329-1340. (Pubitemid 46658686)
58. Ayoub MA, Trinquet E, Pfleger KD, Pin JP. Differential association modes of the thrombin receptor PAR1 with Galphai1, Galpha12, and beta-arrestin 1. FASEB J. 2010;24(9):3522-3535.
59. Bae JS, Yang L, Rezaie AR. Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost. 2008;6(6):954-961. (Pubitemid 351689917)
60. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature. 1997;386(6625):616-619. (Pubitemid 27175428)
61. Kazes I, Elalamy I, Sraer JD, Hatmi M, Nguyen G. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood. 2000; 96(9):3064-3069.
62. Cecchetti L, Tolley ND, Michetti N, Bury L, Weyrich AS, Gresele P. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood. 2011;118(7): 1903-1911.
63. Chesney CM, Harper E, Colman RW. Human platelet collagenase. J Clin Invest. 1974;53(6): 1647-1654.
64. Eckart RE, Uyehara CF, Shry EA, Furgerson JL, Krasuski RA. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J Interv Cardiol. 2004; 17(1):27-31. (Pubitemid 38326510)
65. Gaubatz JW, Ballantyne CM, Wasserman BA, et al. Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. Arterioscler Thromb Vasc Biol. 2010;30(5): 1034-1042.
66. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8(11):1227-1234. (Pubitemid 35373553)
67. Nikkari ST, O'Brien KD, Ferguson M, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 1995;92(6): 1393-1398.
68. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis: implications for plaque rupture. Arterioscler Thromb Vasc Biol. 1996;16(8):1070-1073. (Pubitemid 26266909)
69. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90(4):1614-1621.
70. Cheung WM, D'Andrea MR, Andrade-Gordon P, Damiano BP. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler Thromb Vasc Biol. 1999;19(12):3014-3024. (Pubitemid 30029832)
71. Chieng-Yane P, Bocquet A, Letienne R, et al. Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor alpha and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells. J Pharmacol Exp Ther. 2011;336(3):643-651.
72. Kogushi M, Matsuoka T, Kuramochi H, et al. Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats. Eur J Pharmacol. 2011;666(1):158-164.
73. Deguchi JO, Aikawa E, Libby P, et al. Matrix metalloproteinase-13/ collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation. 2005; 112(17):2708-2715. (Pubitemid 41532609)
74. Prescott MF, Sawyer WK, Von Linden-Reed J, et al. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann N Y Acad Sci. 1999;878:179-190. (Pubitemid 29353569)
75. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 2001;293(5535):1666-1670. (Pubitemid 32807847)
76. Sabri A, Muske G, Zhang H, et al. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res. 2000; 86(10):1054-1061. (Pubitemid 30367864)
77. Pawlinski R, Tencati M, Hampton CR, et al. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation. 2007;116(20):2298-2306. (Pubitemid 350100336)
78. Ellertsdottir E, Berthold PR, Bouzaffour M, et al. Developmental role of zebrafish protease-activated receptor 1 (PAR1) in the cardio-vascular system. PLoS One. 2012;7(7):e42131.
79. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004; 114(5):321-327. (Pubitemid 39422563)
80. Pawlinski R, Mackman N. Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med. 2004; 32(5 suppl):S293-S297.
81. van der Poll T, de Boer JD, Levi M. The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis. 2011;24(3):273-278.
82. Kaneider NC, Leger AJ, Kuliopulos A. Therapeutic targeting of molecules involved in leukocyteendothelial cell interactions. FEBS J. 2006; 273(19):4416-4424. (Pubitemid 44401593)
83. Garcia JG, Davis HW, Patterson CE. Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J Cell Physiol. 1995;163(3):510-522.
84. Vouret-Craviari V, Bourcier C, Boulter E, van Obberghen-Schilling E. Distinct signals via Rho GTPases and Src drive shape changes by thrombin and sphingosine-1-phosphate in endothelial cells. J Cell Sci. 2002;115(12):2475- 2484. (Pubitemid 34778065)
85. Pawlinski R, Pedersen B, Schabbauer G, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood. 2004;103(4):1342-1347. (Pubitemid 38168646)
86. Zhang P, Gruber A, Kasuda S, et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation. 2012;126(1):83-91.
87. Fressinaud E, Sakariassen KS, Rothschild C, Baumgartner HR, Meyer D. Shear rate-dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and hemophilia A. Blood. 1992;80(4): 988-994.
88. InauenW, Baumgartner HR, Bombeli T, Haeberli A, Straub PW. Dose- and shear rate-dependent effects of heparin on thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood. Arteriosclerosis. 1990;10(4):607-615. (Pubitemid 20220585)
89. Gast A, Tschopp TB, Baumgartner HR. Thrombin plays a key role in late platelet thrombus growth and/or stability: effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb. 1994;14(9):1466-1474.
90. Okorie UM, Denney WS, Chatterjee MS, Neeves KB, Diamond SL. Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow. Blood. 2008;111(7): 3507-3513.
91. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol. 1996;16(1):28-33. (Pubitemid 26026928)
92. de Smet BJ, de Kleijn D, Hanemaaijer R, et al. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation. 2000;101(25):2962-2967. (Pubitemid 30415888)
93. Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol. 2004;24(1): 54-60. (Pubitemid 38082411)
94. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res. 2002;91(9):845-851. (Pubitemid 35285083)
95. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res. 1996;78(1):38-43. (Pubitemid 26004118)
96. Cherr GS, Motew SJ, Travis JA, et al. Metalloproteinase inhibition and the response to angioplasty and stenting in atherosclerotic primates. Arterioscler Thromb Vasc Biol. 2002;22(1):161-166. (Pubitemid 34076248)
97. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res. 2006;69(3):677-687. (Pubitemid 43139730)
98. Margolin L, Fishbein I, Banai S, et al. Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha(v)beta(3) receptor blockade. Atherosclerosis. 2002;163(2): 269-277. (Pubitemid 34615817)
99. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des. 2007;13(3):333-346. (Pubitemid 46085282)
100. Axisa B, Loftus IM, Naylor AR, et al. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke. 2002;33(12):2858-2864. (Pubitemid 35462856)
101. Pires PW, Rogers CT, McClain JL, Garver HS, Fink GD, Dorrance AM. Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2011;301(1): H87-H97.
102. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol. 2002;160(3):1089-1095. (Pubitemid 34224595)
103. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol. 2004;24(4):733-738. (Pubitemid 38451612)
104. Yarbrough WM, Mukherjee R, Brinsa TA, et al. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg. 2003;125(3): 602-610. (Pubitemid 36373906)
105. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87(4): 1285-1342. (Pubitemid 350041472)
106. Hudson MP, Armstrong PW, Ruzyllo W, et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006;48(1): 15-20. (Pubitemid 43929218)
107. Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 2001; 103(18):2303-2309. (Pubitemid 32433722)
108. Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002;105(16):1983-1988. (Pubitemid 34437628)
109. Kaludercic N, Lindsey ML, Tavazzi B, Lazzarino G, Paolocci N. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. 2008;26(1):24-37. (Pubitemid 351421776)
110. Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999; 99(23):3063-3070. (Pubitemid 29270438)